에서 실시간으로 운영 중이에요! 자세히 알아보기

Allurion Technologies

ALUR

시가총액 US$1003만

상장 폐지됨

ALUR은(는) 2026년 3월 6일에 상장 폐지됐어요.

순위로 돌아가기

소개: Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.

직원 수: 137

건강관리 의료기기

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 0%

중립 0%

부정적 0%

NYSE to Commence Delisting Proceedings Against Allurion Technologies, Inc. (ALUR)

NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the two securities enumerated below (“Securities”) of Allurion Technologies, Inc. (the “Company”) from the NYSE. NYSE Regulation reached its decision to commence proceedings to delist the Company's Securities pursuant to Section 802.01B of the NYSE's Listed Company Manual because the Company had fallen below the NYSE's.

NYSE to Commence Delisting Proceedings Against Allurion Technologies, Inc. (ALUR)

Allurion Intends to Appeal NYSE Notice of Delisting, Execute Plan to Regain Compliance, and Expects to Continue Trading on NYSE

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, has received notice from the New York Stock Exchange (NYSE) that it intends to initiate delisting proceedings against Allurion after the Company was unable to demonstrate that it had regained compliance with Section 802.01B of the Listed Company Manual requiring listed companies to maintain either (i) at least $50 million in stockholders' equity or (ii) at le.

Allurion Intends to Appeal NYSE Notice of Delisting, Execute Plan to Regain Compliance, and Expects to Continue Trading on NYSE

NYSE to Commence Delisting Proceedings Against Allurion Technologies, Inc. (ALUR)

NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the two securities enumerated below (“Securities”) of Allurion Technologies, Inc. (the “Company”) from the NYSE. Trading in these Securities will continue on the NYSE until such time as described below. Symbol Description ALUR Common stock, par value $0.0001 per share ALUR WS Warrants to purchase 0.056818 shares of com.

NYSE to Commence Delisting Proceedings Against Allurion Technologies, Inc. (ALUR)

Zacks Investment Research

Are Medical Stocks Lagging Allurion Technologies, Inc. (ALUR) This Year?

Here is how Allurion Technologies, Inc. (ALUR) and McKesson (MCK) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Allurion Technologies, Inc. (ALUR) This Year?

Allurion Announces Exercise of Warrants for $3.0 Million in Gross Proceeds

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (the “Company” or “Allurion”), a pioneer in metabolically healthy weight loss, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,659,565 shares of common stock, issued by the Company on January 27, 2025 (the “January 2025 Warrants”), February 20, 2025 (the “February 2025 Warrants”) and November 12, 2025 (the “November 2025 Wa.

Allurion Announces Exercise of Warrants for $3.0 Million in Gross Proceeds

Allurion Receives U.S. FDA Approval

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket approval (PMA) application for the Allurion Gastric Balloon System, featuring the Allurion Smart Capsule. “Today's approval is a watershed moment for Allurion and for obesity care in the United States,” said Dr. Shantanu Gaur, Founder and Chief Executive Officer. “Our goal is to deliv.

Allurion Receives U.S. FDA Approval

Allurion Announces Partnership to Offer Combination Therapy with Mounjaro® (tirzepatide) at Discounted Prices

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced a partnership with Bionut, a leader in obesity care in Argentina, and Farmastar, a local pharmacy partner with access to the official supplier of Mounjaro (tirzepatide) in Argentina, to provide patients with access to discounted Mounjaro to be used in combination with the Allurion Smart Capsule. “The obesity epidemic is growing, and patients are in need of mo.

Allurion Announces Partnership to Offer Combination Therapy with Mounjaro® (tirzepatide) at Discounted Prices

Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced preliminary, unaudited results for the fourth quarter and full year 2025. Management expects preliminary, unaudited results for the period as follows: Fourth quarter revenue of $3.3 million to $3.7 million, a 22% to 37% increase quarter-over-quarter, and full-year revenue of approximately $15 million Substantial improvement in operating expenses and operating.

Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results

Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced initial results on the combination of the Allurion Program with low-dose tirzepatide therapy to optimize muscle mass and GLP-1 adherence. 76 patients treated with the Allurion Smart Capsule were started on low-dose tirzepatide after completing their first 45 days of balloon therapy. The starting dose of tirzepatide was 2.5mg and.

Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence

New Peer-Reviewed Publication Demonstrates Superior Weight Loss and Improved Body Composition with the Allurion Smart Capsule Combined with Lifestyle Intervention Compared to Lifestyle Intervention Alone

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced the publication of a peer-reviewed, case-controlled study on the use of the Allurion Smart Capsule combined with lifestyle intervention compared to lifestyle intervention alone and its impact on weight loss and body composition. Published in Obesity Surgery, a leading international journal dedicated to the treatment of obesity and metabolic disease, results f.

New Peer-Reviewed Publication Demonstrates Superior Weight Loss and Improved Body Composition with the Allurion Smart Capsule Combined with Lifestyle Intervention Compared to Lifestyle Intervention Alone

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.